Condition

Non-small Cell Lung Adenocarcinoma

ClinicalTrials.gov condition label

Clinical trials2

Recruiting0

Common interventions3

Lead sponsors shown2

Clinical trials

2 shown

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced CancersNCT05873686 · 2023-10-26

ACTIVE_NOT_RECRUITING

A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell CarcinomaNCT05943795 · 2023-07-14

ACTIVE_NOT_RECRUITING

Common interventions

DocetaxelDRUG1NXP900DRUG1SI-B001DRUG1

Leading sponsors

Nuvectis Pharma, Inc.1Sichuan Baili Pharmaceutical Co., Ltd.1

Trial status mix

ACTIVE_NOT_RECRUITING2

Phase mix

PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.